RUPINDER KAUR: Open Payments
NPI 1467231241 · WAYNE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,570 in 71 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $584 · 2025 $1,570
Food & beverage: $1,570
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $429 |
| Otsuka America Pharmaceutical, Inc. | 14 | $422 |
| Alkermes, Inc. | 8 | $253 |
| E.R. Squibb & Sons, L.L.C. | 2 | $151 |
| Neurocrine BioSciences, Inc. | 5 | $106 |
| Teva Pharmaceuticals USA, Inc. | 3 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Corium, LLC | 1 | $22 |
Products named: VRAYLAR, REXULTI, LYBALVI, COBENFY, INGREZZA, ARISTADA, UZEDY, CAPLYTA.
Industry payments across NJ — which companies pay providers there.
